KR20200070091A - Nano-lipid carrier for encapsulation of physiologically active substance and preparation method thereof - Google Patents

Abstract

The present invention relates to a particulate nano-lipid carrier for encapsulation of physiologically active substances, and to a production method thereof and, more specifically, to a particulate nano-lipid carrier having excellent nano-particle stability and improved encapsulation of water-soluble drugs, wherein the nano-lipid carrier according to the present invention has significantly improved stability and encapsulation efficiency of physiologically active substances compared to a conventional delivery system, and is expected that the nano-lipid carrier through the present invention can be directly commercialized as a cosmetic raw material as a method for targeting hair follicles suitable for mass production.

Description

Nano-lipid carrier for encapsulation of physiologically active substance and preparation method thereof

The present invention relates to a nanolipid transporter for encapsulating a bioactive material and a method for manufacturing the same, and more particularly, to a particulate nanolipid transporter having excellent nanoparticle stability and improved encapsulation of a water-soluble drug.

The importance of developing a drug delivery system capable of efficiently delivering drugs in the human body is increasing. Among the drug delivery systems, the technology of encapsulating and using the drug in a micro or nano-sized carrier can be variously used for injection, oral or transdermal use, and representative technologies include emulsions, liposomes, microparticles, or nanoparticles. The structure of the.

The emulsion is a structure in which a drug is enclosed in an oil droplet and dispersed using an amphiphilic surfactant, which is very effective in dissolving poorly soluble drugs, but has low physical stability. Liposomes are colloidal nanocarriers, which can circulate in the blood for a long time, have biocompatibility, and reduce the toxicity of bioactive substances, but have a high probability of loss due to phagocytosis of macrophages and colloidally unstable disadvantages. In addition, polymer microparticles or nanoparticles are advantageous for controlling drug release, targeting, etc., and have the advantage of producing various types of particles by controlling to a desired particle size. There are drawbacks and disadvantages that mass production is not easy.

Recently, solid lipid nanoparticles that overcome the disadvantages of the drug delivery system as described above have been actively studied as a new structure. Solid lipid nanoparticles are structures that exist in the form of encapsulating the drug inside the solid lipid by encapsulating the drug using solid lipids at room temperature and producing spherical particles. Solid lipid nanoparticles increase the temperature of solid lipids, mix with hydrophobic drugs, form particles through a surfactant and cool in the water phase, so it is advantageous to encapsulate hydrophobic drugs, but hydrophilic drugs such as peptides are very high at 20-30%. It has the disadvantage of showing a low encapsulation rate. In order to overcome the above problems, a method of binding a hydrophilic drug with hydrophobicity, a method of preparing in an emulsion form, a method of binding a lipid in a liquid crystal state, etc. has been studied, but not only a significant improvement in the encapsulation rate has not been achieved, The problem remains that mass production is difficult.

There are two methods of non-invasive delivery to the skin among drug delivery routes, transdermal delivery and hair follicle delivery. As a result of studies until recently, when nanosized the size of a carrier, the probability of passing through keratinocytes to the dermis is much higher than that of a carrier having a micro or larger size. Representative transdermal delivery systems include liposomes that encapsulate drugs with phospholipids, and are widely used in drug delivery and cosmetics, but the transdermal delivery system shows a remarkably lower tendency in transdermal delivery than the theory, and is a colloidal delivery system. Since there is a disadvantage that stability is very low, the solution to this problem is urgent.

Republic of Korea Registered Patent Publication No. 1810160 (Dec. 12, 2017) Republic of Korea Registered Patent Publication No. 1054731 (2011.08.01) Republic of Korea Registered Patent Publication No. 1377710 (2014.03.17)

Unlike conventional solid lipid nanoparticles, which have low encapsulation efficiency for water-soluble physiologically active substances and are mainly used only as carriers for fat-soluble bioactive substances, the object of the present invention is to use nanolipid carriers as carriers for water-soluble bioactive substances and It is intended to significantly improve the encapsulation efficiency of bioactive materials.

Another object of the present invention is to solve the problem that the structure of the solid lipid nanoparticles is collapsed due to low stability even if the water-soluble physiologically active material is encapsulated, and it is possible to stably encapsulate the water-soluble physiologically active material. It is to provide a lipid transporter and a nanolipid transporter that can stably have colloidal stability for a long time in an aqueous dispersion state.

Another object of the present invention is to provide solid lipid nanoparticles with excellent absorption efficiency specifically for hair follicles when treated on skin.

A method of manufacturing a nanolipid transporter encapsulated with a physiologically active material according to the present invention comprises the steps of: generating an aqueous solution of a hydrophilic polymer complex comprising a bioactive material and a hydrophilic polymer; Generating a colloidal solution by introducing the aqueous hydrophilic complex solution into a phospholipid solution; Generating a water-in-oil dispersion by adding the colloidal solution to lipids; And adding the water-in-oil dispersion to an aqueous solution containing a surfactant and homogenizing to generate a nanolipid transporter.

In the method of manufacturing a nanolipid transporter according to an embodiment of the present invention, the bioactive material may include a peptide-based compound.

In the method of manufacturing a nanolipid transporter according to an embodiment of the present invention, the bioactive material may have a positive or negative charge in an aqueous solution.

In the method of manufacturing a nanolipid transporter according to an embodiment of the present invention, the hydrophilic polymer may include anionic or cationic polymers, and may have different charges from upper physiological substances .

In the method of manufacturing a nanolipid transporter according to an example of the present invention, the aqueous hydrophilic polymer composite solution may exhibit hydrogel properties.

In the method of manufacturing a nanolipid transporter according to an embodiment of the present invention, the lipid may include two or more lipids having different melting points.

In the method of manufacturing a nanolipid transporter according to an example of the present invention, the lipid mixture may include a first lipid that is solid at room temperature and a second lipid that is liquid at room temperature.

In the method of manufacturing a nanolipid transporter according to an embodiment of the present invention, the water-in-oil dispersion may be prepared by mixing the colloidal solution after heating the lipid to form a solution phase.

In the method of manufacturing a nanolipid transporter according to an embodiment of the present invention, the surfactant may include an aliphatic glyceryl-based compound.

In the method of manufacturing a nanolipid transporter according to an embodiment of the present invention, the solvent of the phospholipid solution may include alcohol.

In the method of manufacturing a nanolipid transporter according to an embodiment of the present invention, the colloidal solution may include an ethosomal colloid.

In the method of manufacturing a nanolipid transporter according to an embodiment of the present invention, the step of generating the nanolipid transporter may further include a high pressure emulsification step.

In addition, the nanolipid transporter according to the present invention includes a core portion including a hydrophilic polymer complex containing a bioactive material and a hydrophilic polymer; And a shell portion located on the surface of the core and including lipids. The core portion further includes phospholipids.

In the nanolipid transporter according to an embodiment of the present invention, the lipid and phospholipid may be included in a weight ratio of 100:0.1 to 100:50.

In the nanolipid transporter according to an embodiment of the present invention, the bioactive material and the hydrophilic polymer may be included in a weight ratio of 2000:1 to 20:1.

In the nanolipid transporter according to an embodiment of the present invention, the nanolipid transporter has an average particle diameter of 20 nm to 1000 nm and may satisfy the following relational expression 1.

[Relationship 1]

|T ₀ -T ₂₀ |/T ₀ <0.2

(In the above equations 1 T ₀ after the production of nano-lipid delivery system of 1% aqueous dispersion by weight means a permeability measured at 500 nm wavelength, and, T ₂₀ are 500 then the nano-lipid delivery system of 1% aqueous dispersion by weight to stand at 45 ℃ 20 il It means transmittance measured at nm wavelength.)

In addition, the present invention provides a cosmetic composition comprising the nanolipid transporter.

The cosmetic composition according to an embodiment of the present invention may have follicle targeting properties and may be a transdermal absorption cosmetic composition.

In addition, the present invention provides a method for delivering follicular targeting of a nanolipid transporter encapsulated with a bioactive substance, comprising the step of treating the nanolipid transporter on the skin.

The nanolipid transporter according to the present invention can be preferably used as a carrier of a water-soluble bioactive material by encapsulating the water-soluble bioactive material with a high content therein.

In addition, the nanolipid transporter according to the present invention can stably encapsulate a water-soluble physiologically active substance, and can have colloidal stability stably for a long time in an aqueous dispersion state.

In addition, the nanolipid transporter according to the present invention has a particularly excellent absorption rate for hair follicles when treated on the skin, and is capable of mass production in a relatively simple manufacturing method, and thus is preferable as a pharmaceutical composition or cosmetic composition for delivering a physiologically active substance to the hair follicle. Can be used.

1 shows a schematic diagram of the structure of a nanolipid transporter in which a bioactive material is encapsulated according to an example of the present invention.
Figure 2 shows the results of measuring the particle size of the nanolipid transporter prepared according to an example of the present invention.
Figure 3 shows the results of taking a sample after a 30-day stability test of the nanolipid transporter dispersion (solid content 6.5% by weight) according to an example of the present invention.
Figure 4 shows the results of measuring the nanolipid transporter according to an embodiment of the present invention by bio-TEM.
FIG. 5 shows the results of confocal fluorescence measurement of the nanolipid transporter absorbed by the skin follicle and fluorescent treatment of the nanolipid transporter according to an embodiment of the present invention.
Figure 6 shows the results of the test is absorbed by targeting the nano-lipid transporter in the hair follicle according to an embodiment of the present invention.

Hereinafter, the present invention will be described in detail with reference to the accompanying drawings. The drawings introduced below are provided as examples in order to sufficiently convey the spirit of the present invention to those skilled in the art. Therefore, the present invention is not limited to the drawings presented below and may be embodied in other forms, and the drawings presented below may be exaggerated to clarify the spirit of the present invention.

Unless otherwise defined in the technical terms and scientific terms used in the specification of the present invention, those skilled in the art to which the present invention pertains have the meanings commonly understood, and the present invention in the following description and accompanying drawings Descriptions of well-known functions and configurations that may unnecessarily obscure the subject matter are omitted.

Also, the singular form used in the specification of the present invention may be intended to include the plural form unless otherwise specified in the context.

In addition, in the specification of the present invention, the units used without specific reference are based on weight, and for example, units of% or ratio mean weight percent or weight ratio.

Also, unless otherwise defined in the specification of the present invention, the molecular weight of the polymer means the weight average molecular weight.

Also, unless otherwise defined in the specification of the present invention, the average particle diameter of the particles means D50 obtained through a particle size analyzer.

In addition, in the specification of the present invention, the expression “includes” is an open description having the meaning equivalent to expressions such as “have”, “contains”, “haves” or “makes a feature”, and is additionally listed. It does not exclude elements, materials or processes that are not present. Also, “actually… The phrase “consisting of” means that a specified element, material, or process, along with other elements, materials, or processes not listed, does not have an unacceptably significant effect on at least one basic and novel technical idea of the invention. It means that it can exist in quantity. Also, the expression “consisting of” means that only the elements, materials, or processes described are present.

In addition, in the specification of the present invention, a hydrogel means a solid material including a hydrophilic polymer having swelling property using water as a solvent, and has high viscosity, which means that it is substantially unmodified or has low fluidity.

Hereinafter, a method of manufacturing a nanolipid transporter encapsulated with a bioactive material according to the present invention will be described in detail.

The present invention comprises the steps of producing an aqueous solution of a hydrophilic polymer complex comprising a bioactive material and a hydrophilic polymer; Generating a colloidal solution by introducing the aqueous hydrophilic complex solution into a phospholipid solution; Generating a water-in-oil dispersion by adding the colloidal solution to lipids; And adding the water-in-oil dispersion to an aqueous solution containing a surfactant and homogenizing to generate a nanolipid transporter; It provides a method for producing a nanolipid transporter containing a bioactive material containing.

In the step of producing an aqueous solution of a hydrophilic polymer complex containing the bioactive substance and the hydrophilic polymer, the bioactive substance is not limited to a range such as a bioactive substance for cosmetics or a bioactive substance for medicine, preferably water-soluble physiological activity It can be a substance. The water-soluble physiologically active substance may be any substance having a physiologically active effect, but one embodiment of the present invention may include a peptide, and the following description specifically describes the peptide as a physiologically active substance, but is not limited thereto. .

The peptide-based compound may include, for example, 2 to 1000, preferably 2 to 100, and more preferably 2 to 10 amino acids, but is not limited thereto.

In the peptide-based compound, a peptide is a substance in which two or more amino acids are covalently linked, and is absorbed through a cell membrane, thereby exhibiting physiological activity in cells and tissues. Specific examples of the peptides include copper peptide (GHK-Cu), alanine/histidine/lysine polypeptide copper HCl, acetyldecapeptide-3, and acetyloligopeptide-2 amide , Acetyltetrapeptide-2, acetyltetrapeptide-3, acetyltetrapeptide-5, acetyltetrapeptide-9, acetyltetrapeptide-11, acetyltetrapeptide-15, acetyltetrapeptide-17, acetyltetrapeptide-22, acetyl Tetrapeptide-40, acetyltripeptide-1, acetylpentapeptide-1, acetylpentapeptide-55amide, acetylhexapeptide-1, acetylhexapeptide-8, acetylhexapeptide-22, acetylhexapeptide-30, acetylhexa Peptide-37, acetylhexapeptide-38, acetylhexapeptide-39, acetylhexapeptide-49, acetylhexapeptide-51amide, acetylheptapeptide-4, acetylheptapeptide-9, palmitoyltetrapeptide-3, palmitoyl Tetrapeptide-7, palmitoylpentapeptide-3, palmitoylpentapeptide-4, palmitoylpentapeptide-5, palmitoyltripeptide-1, palmitoyltripeptide-5, palmitoyltripeptide-8, palmitoyltri Peptide-29, palmitoyl tripeptide-36, palmitoyl tripeptide-38, palmitoyl tripeptide-40, palmitoylhexapeptide-12, palmitoylhexapeptide-14, palmitoylhexapeptide-15, palmitoylhexapeptide -56, palmitoyl hepta peptide-5, copper tripeptide-1, oligopeptide-1, oligopeptide-2, oligopeptide-3, oligopeptide-4, oligopeptide-5, oligopeptide-6, oligopeptide-7 , Oligopeptide-11, oligopeptide-14, oligopeptide-18, oligopeptide-20, oligopeptide-24, oligopeptide-27, oligopeptide-28, oligopeptide-29, oligopeptide-30, oligopeptide-31 , Oligopeptide-32, oligopeptide-34, oligopeptide-41, oligopeptide-42, oligopeptide DE-50, oligopeptide-51, oligopeptide-52, oligopeptide-54, oligopeptide-55, oligopeptide-57, oligopeptide-58, oligopeptide-59, oligopeptide-61, oligopeptide-62, oligo Peptide-66, oligopeptide-68, oligopeptide-70, oligopeptide-71, oligopeptide-72, oligopeptide-73, oligopeptide-74, oligopeptide-75, oligopeptide-76, oligopeptide-79, oligo Peptide-86, oligopeptide-88, oligopeptide-92, R-oligopeptide-1, R-oligopeptide-2, R-oligopeptide-4, R-oligopeptide-33, tripeptide-1 , Tripeptide-2, tripeptide-3, tripeptide-29, tripeptide-31, tripeptide-32, tripeptide-47, tripeptide-48, tripeptide-56, tetrapeptide-3, tetrapeptide-4 , Tetrapeptide-7, tetrapeptide-14, tetrapeptide-21, tetrapeptide-26, tetrapeptide-30, tetrapeptide-32, tetrapeptide-42, tetrapeptide-44, tetrapeptide-51, tetrapeptide-56 , Tetrapeptide-57, tetrapeptide-58, tetrapeptide-59, nicotinoyl hexapeptide-44, nicotinoyl hexapeptide-45, nicotinoyl hexapeptide-56, nicotinoyl dipeptide-22, nicotino One dipeptide-23, nicotinoyl dipeptide-24, nicotinoyl dipeptide-26, nicotinoyl tripeptide-1, nicotinoyl tripeptide-35, nicotinoyl tripeptide-47, nicotinoyl tripeptide Peptide-48, Nicotinoyloctapeptide-9, Nicotinoylpentapeptide-20, Nicotinoylpentapeptide-33, Galoylnonapeptide-11, Galoyltetrapeptide-19, Galoyltripeptide-47, Gallo Iltripeptide-48, Galoyltripeptide-35, Galoyltripeptide-7, Galoylpentapeptide-33, Galoylhexapeptide-44, Digaloyltetrapeptide-19, Decapeptide-2, Decapeptide- 4, decapeptide-6, decapeptide -10, decapeptide-11, decapeptide-12, decapeptide-15, decapeptide-16, decapeptide-18, decapeptide-19, decapeptide-20, decapeptide-23, decapeptide-25, decapeptide -28, decapeptide-31, retinoyl tripeptide-1, retinoyl tripeptide-35, retinoylpentapeptide-4, manganese tripeptide-1, mevalonoylpentapeptide-37, mevalonoylpentapeptide- 39, mevalonoyl tripeptide-1, mevalonoyl tripeptide-35, mevalonoyl tetrapeptide-36, myristoyltetrapeptide-6, myristoyltetrapeptide-8, myristoyltetrapeptide-34, Myristoyl tripeptide-31, myristoylpentapeptide-8, myristoylpentapeptide-9, myristoylpentapeptide-17, biotinoyl tetrapeptide-51, biotinoyl tripeptide-1, biotino Iltripeptide-35, biotinoyl pentapeptide-4, valpro oil oligopeptide-33, cafe oil decapeptide-17, cafe oil oligopeptide-77, cafe oil tripeptide-1, cafe oil tripeptide-7, Cafe oil tripeptide-35, cafe oil pentapeptide-20, cafe oil pentapeptide-27, cafe oil hexapeptide-48, cafe oil hexapeptide-50, cafe oil hexapeptide-56, cafe oil hexapeptide-65, cafe Oil Heptapeptide-11, S-polypeptide-1, S-polypeptide-2, S-polypeptide-3, S-polypeptide-4, S-polypeptide-5, S-polypeptide-6, S- Polypeptide-7, S-polypeptide-8, S-polypeptide-9, S-polypeptide-10, S-polypeptide-11, S-polypeptide-13, S-polypeptide-15, S-poly Peptide-16, S-polypeptide-17, S-polypeptide-18, S-polypeptide-19, S-polypeptide-22, S-polypeptide-25, S-polypeptide-26, S-polypeptide -28, S-Polypeptide D-29, S-polypeptide-31, S-polypeptide-33, S-polypeptide-34, S-polypeptide-35, S-polypeptide-36, S-polypeptide-37, S-polypeptide -38, S-polypeptide-39, S-polypeptide-40, S-polypeptide-41, S-polypeptide-42, S-polypeptide-43, S-polypeptide-44,S-polypeptide- 45, S-polypeptide-46, S-polypeptide-50, S-polypeptide-53, S-polypeptide-54, S-polypeptide-55, S-polypeptide-56, S-polypeptide-58 , S-polypeptide-59, S-polypeptide-60, S-polypeptide-62, S-polypeptide-64, S-polypeptide-66, S-polypeptide-70, S-polypeptide-71, S-polypeptide-74, S-polypeptide-78, S-polypeptide-81, S-polypeptide-85, R-polypeptide-1, R-polypeptide-2, R-polypeptide- 3, R-polypeptide-4, R-polypeptide-5, R-polypeptide-6, R-polypeptide-7, R-polypeptide-8, R-polypeptide-9, R-polypeptide-10, R-polypeptide-11, R-polypeptide-13, R-polypeptide-14, R-polypeptide-15, R-polypeptide-22, R-H -Polypeptide-26, R-polypeptide-28, R-polypeptide-33, R-polypeptide-51, R-polypeptide-53, R-poly-peptide-58, R-poly Peptide-59, R-polypeptide-60, R-polypeptide-62, R-polypeptide-64, R-polypeptide-66, R-polypeptide-67, nonapeptide-1, nona Peptide-10, Nonapeptide- 11, nonapeptide-16, nonapeptide-18, nonapeptide-19, oat peptide, soybean polypeptide, dipeptide-1, dipeptide-15, wheat peptide, salicyloyl octapeptide-9, salicyloyl pentapeptide -33, Shikimoyl nonapeptide-11, Shikimoyl pentapeptide-33, Shikimoyl hexapeptide-48, Azela oil octapeptide-9, Azela oil tripeptide-1, Azela oil pentapeptide-37, Pea peptide, Ursolo Iltetrapeptide-37, ursoloyl tripeptide-1, ursoloyl tripeptide-35, ursoloyl pentapeptide-4, thiotoyl tripeptide-1, thiotoyl tripeptide-35, thiotoyl penta Peptide-4, Copper Palmitoyl Hepteptide-14, Caproyl Tetrapeptide-3, Capryloyl Dipeptide-17, Capryloyl Heptapeptide-33, Quinoyl Tripeptide-1, Quinoyl Tripeptide-7, Qui Noyl tripeptide-35, cocoyl pentapeptide-9, couromayl nonapeptide-29, couromayl dipeptide-3, pentapeptide-3, pentapeptide-13, pentapeptide-18, pentapeptide-20, pentapeptide -27, pentapeptide-28, pentapeptide-31, pentapeptide-36, pentapeptide-37, pentapeptide-44, pentapeptide-45, pentapeptide-46, pentapeptide-48, pentapeptide-54, pentapeptide -56, pentapeptide-57, hexapeptide-2, hexapeptide-3, hexapeptide-9, hexapeptide-10, hexapeptide-11, hexapeptide-12, hexapeptide-17, hexapeptide-33, hexapeptide -42, hexapeptide-43, hexapeptide-47, hexapeptide-57, hexapeptide-61, hexapeptide-62, hexapeptide-63, hexapeptide-65, heptapeptide-10, heptapeptide-12, heptapeptide -13, heptapeptide-16, heptapeptide-22, heptapeptide-36, heptapeptide-37, heptapeptide-38, heptapeptide-39, heptapeptide-40, yeast polypeptide, feruloyl oligopeptide-33, Tranexamoyl dipeptide-22, cozylcarboxydipeptide-23, octapeptide-2, octapeptide- 7, octapeptide-8, octapeptide-10, octapeptide-11, octapeptide-15, and the like, but are not limited thereto.

In addition, the bioactive material is not limited as long as it does not inhibit the object of the present invention, but may have a positive or negative charge in an aqueous solution.

A cationic peptide having a positive charge in an aqueous solution contains a large number of cationic amino acids, and may refer to a peptide having a pKa of 5 or more, specifically 6 or more, and more specifically 8 or more. More specifically, the amount of the charge means that measured in a neutral aqueous solution of pH 7. The cationic peptide may preferably include a large number of H, K, R in the peptide sequence. Preferably, the cationic peptide may include two or more amino acids selected from the group consisting of H, K and R, and the proportion of cationic amino acids in the primary sequence constituting the cationic peptide is 20% or more, preferably 30 %, more preferably 50% or more.

The anionic peptide having a negative charge in the aqueous solution contains a large number of anionic amino acids, and may mean a peptide having a pKa of 5 or less, specifically 4 or less. More specifically, the negative charge means measured in a neutral aqueous solution of pH 7. The anionic peptide may preferably include a plurality of D and E in the peptide sequence. Preferably, the anionic peptide may include two or more amino acids selected from the group consisting of D and E, and the proportion of anionic amino acids in the primary sequence constituting the anionic peptide is 20% or more, preferably 30%. , More preferably 50% or more.

The hydrophilic polymer may have a weight average molecular weight of 10,000 or more, specifically 50,000 or more, and more specifically 100,000 or more and 5,000,000 or less.

The hydrophilic polymer is not limited as long as it does not inhibit the object of the present invention, but includes an anionic or cationic polymer, and may have a different charge from a physiological substance.

Examples of the types of anionic groups included in the anionic polymer include, but are not limited to, carboxyl groups, sulfonic acid groups, sulfate ester groups, phosphoric acid groups, and the like. The anionic polymer may be a synthetic polymer, a saccharide polymer, a polyamino acid polymer, and derivatives thereof. Specific examples of anionic polymers include polyglutamic acid, polyacrylic acid, carbomer, alginate, carrageenan, hyaluronic acid, polystyrene sulfonate styrene sulfonate), carboxymethylcellulose, Cellulose sulfate, Dextran sulfate, Heparin, Pectin, Heparin sulfate, Polymethylenecoguanidine (Poly(methylene- co-guanidine)) and chondroitin sulfate, but is not limited thereto.

Examples of cationic groups included in the cationic polymer include primary amino groups, secondary amino groups, tertiary amino groups, sulfonium groups or phosphonium groups, but are not limited thereto. The cationic polymer may be a synthetic polymer, a saccharide polymer, a polyamino acid polymer, and derivatives thereof. Specific examples of the cationic polymer may be selected from the group consisting of polyethyleneimine, polylysine, polyhistidine, polyarginine, Polyquaternium-10 and chitosan, but is not limited thereto.

The aqueous hydrophilic polymer composite solution is not limited as long as it does not inhibit the object of the present invention, but may exhibit hydrogel properties. Hydrogel, also called hydrogel, refers to a hydrated polymer in which the water-soluble polymer is highly viscous by hydrogen bonding, van der Waals forces, hydrophobic interactions, or crystal or chemical covalent bonding of the polymer, and contains a significant amount of water in the water phase It has the ability to do it. The hydrogel may be produced from various anionic or cationic polymers as described above, may have various chemical compositions and may also have a structure of a copolymer or a substituted derivative.

More specifically, when a cationic peptide is selected as a bioactive material and an anionic polymer is selected as a hydrophilic polymer, the anionic polymer and the cationic peptide can form an ionic complex, and the cationic peptide is anionic It can stably exist in the form of a complex in the aqueous phase by the sex polymer. Preferably, when the cationic peptide contains two or more cationic residues, the physical cross-linking point can be formed by forming two or more ionic bonds with the anionic group of the anionic polymer, so that the anionic polymer and cationic peptide included in the aqueous phase are It can exhibit more viscous hydrogel properties. Similarly, when an anionic peptide is selected as a bioactive material and a cationic polymer is selected as a hydrophilic polymer, the cationic polymer and anionic peptide may form an ionic complex, and the anionic peptide is added to the cationic polymer. It can stably exist in the form of a complex in the aqueous phase. Preferably, when the anionic peptide contains two or more anionic residues, a physical crosslinking point can be formed by forming two or more ionic bonds with the cationic polymer's cationic polymer, so that the cationic polymer and anionic peptide included in the aqueous phase are It can exhibit more viscous hydrogel properties.

The total number of moles of cation residues of the cationic peptide may be the same or more than the total number of moles of anion residues of the anionic polymer, preferably, the total number of moles of the cation residues may be greater than the number of moles of the anion residues, As a non-limiting example, it may be 10 to 100 times more. Similarly, since the relationship between the total number of moles of anionic residues of anionic peptides and the total number of moles of cationic residues of cationic polymers is the same as above, detailed descriptions are omitted.

When preparing the aqueous solution of the hydrophilic polymer composite, the bioactive substance with respect to water as a solvent may be included in a range of 0.01% to 50% by weight, specifically 0.1% to 20% by weight, and more specifically 0.5% to 10% by weight. have. In addition, the hydrophilic polymer with respect to water as a solvent may be 0.0001 wt% to 1 wt%, specifically 0.001 wt% to 0.1 wt%, more specifically 0.005 wt% to 0.05 wt%, but is not limited thereto.

After producing an aqueous hydrophilic polymer composite solution containing water, a physiologically active substance and a hydrophilic polymer in the content range as described above, the aqueous hydrophilic polymer composite aqueous solution is introduced into a phospholipid solution to produce a colloidal solution.

In the step of generating the colloidal solution, the aqueous solution of the hydrophilic polymer complex exhibiting the hydrogel characteristic is introduced into the phospholipid solution, whereby the phospholipid solution can be hydrated in the aqueous solution of the hydrophilic polymer complex to form a hydrated liquid crystal phase.

The phospholipid can be selected from natural phospholipids and synthetic lipids. Natural phospholipids are egg yolk lecithin (phosphatidylcholine), soybean lecithin, hydrogenated lecithin, lysolecithin, sphingomyelin, phosphatidic acid, phosphatidylserine, phosphatidyl glycerol, phosphatidyl inositol, phosphatidyl inositol, phosphatidyl inositol, Diphosphatidylglycerol, cardiolipin (Cardiolipin) and may be at least one substance selected from the group consisting of plasma, synthetic lipids are disetyl phosphate, distearoylphosphatidylcholine, dioleoyl phosphatidylethanolamine, dipalmitoyl Phosphatidylcholine, dipalmitoylphosphatidylethanolamine, dipalmitoylphosphatidylserine, eleostearoylphosphatidylcholine, eleostearoylphosphatidylethanolamine and eleostearoylphosphatidylserine, but may be at least one substance selected from the group consisting of It is not done.

The solvent of the phospholipid solution is not limited as long as it does not impair the object of the present invention, but may include alcohol, and in the present invention, the alcohol may be selected from lower alcohols having 1 to 4 carbon atoms, but is not limited thereto. As an example of the lower alcohol, methanol, ethanol, propanol, butanol, and the like, more preferably, ethanol may be selected. It is preferable to select a lower alcohol to soften the lipid film of the skin and enhance the absorption rate of the nanolipid transporter.

The phospholipid may be included in a range of 0.1% to 50% by weight, specifically 1% to 40% by weight, and more specifically 10% to 30% by weight with respect to alcohol as a solvent of the phospholipid solution.

The phospholipid solution and the aqueous solution of the hydrophilic polymer composite may be 1:0.1 to 1:10 by weight, specifically 1:0.2 to 1:5, and more specifically 1:0.5 to 1:2. Preferably, the phospholipid solution and the hydrophilic polymer composite aqueous solution may be mixed in a weight ratio of 1:0.9 to 1:1. Phospholipids are hydrated by the water contained in the hydrophilic polymer composite aqueous solution at the above weight mixing ratio to form a hydrated liquid phase.

Specifically, for example, as the phospholipid ethanol solution and the hydrophilic polymer composite aqueous solution are mixed, the ethanol contained in the phospholipid solution and the water contained in the hydrophilic polymer composite aqueous solution are mixed with each other. In the phospholipid solution, the phospholipid forms a uniform solution in an ethanol solvent, but gradually mixes with water to form a liquid crystal phase to form a structure of an ethosome colloid.

The ethosome is a drug delivery system for enhancing the skin absorption effect than the liposome, and can more easily pass through a narrow gap between keratinocytes with a more flexible and easily deformable membrane than the liposome, and can act as a skin penetration enhancer. It is prepared by dissolving phospholipids in ethanol. The ethanol acts with the polar head portion of the lipid to reduce the interfacial tension, thereby reducing the interfacial tension of the lipid membrane present in the stratum corneum and making the membrane of the vesicle itself flexible. Etosome from this is preferable because it can deliver the bioactive substance through the skin barrier more effectively into the skin.

After the colloidal solution is generated by injecting the aqueous hydrophilic complex solution into a phospholipid solution, the colloidal solution may be introduced into a lipid to generate a water-in-oil dispersion.

In the step of generating the water-in-oil dispersion by adding the colloidal solution to the lipid, the lipid may be a compound containing an aliphatic hydrocarbon that is not miscible with water, and the colloidal solution is introduced into the lipid, so that the lipid is a continuous phase. And a water-in-oil dispersion in which the colloidal solution forms a dispersed phase. More specifically, the lipid is not limited as long as it does not inhibit the object of the present invention, but may be a lipid mixed solution containing two or more lipids having different melting points, but is not limited thereto.

The lipid mixture may include a first lipid that is solid at room temperature and a second lipid that is liquid at room temperature. Examples of the first lipid that is solid at room temperature include Apifil (PEG-8 Beeswax), Beeswax, and Carnauba wax 2442 L (Copernicia Cerifera wax), Compritol ATO (Glyceryl Behenate), Cutina CP (Cetyl Palmitate), Dynasan (Trimyristin), Glyceryl stearate, Glyceryl stearate/maleate, Glyceryl stearate/acetate, Stearic acid, It may be at least one substance selected from cetyl palmitate, tristearin, and the like, but is not limited thereto. Examples of the second lipid that is liquid at room temperature include caprylic/capryl triglyceride, paraffin oil, oleic acid, It may be at least one material selected from the group consisting of squaene, octyldodecanol, isopropyl myristate, tocopherol, ethoxydiglycol, and dicetyl phosphate, but is not limited thereto.

The mixing ratio of the first lipid in the solid phase and the second lipid in the liquid phase is not limited as long as it does not impair the object of the present invention, but is 1:0.05 to 1:20, specifically 1:0.1 to 1:10, and more specifically 1 It can be mixed in a weight ratio of :0.5 to 1:5. Preferably, the mixing ratio of the solid first lipid and the liquid lipid may be a weight ratio of 1:0.8 to 1:1.2, and the core portion of the nanolipid transporter can be stably formed in the above range, which is preferable.

As the lipid mixture containing the first lipid, which is solid at room temperature and the second lipid, which is liquid at room temperature, is included as an oil phase, a nano-lipid transporter having a small particle size can be formed without adding high energy during homogenization. It can be stably sealed. In addition, a hydrophilic polymer composite containing a physiologically active substance corresponding to the core portion and a hydrophilic polymer and a lipid mixture liquid corresponding to the shell portion form a fluid oil-water interface, and a hydrated liquid crystal phase by phospholipids is disposed at the oil-water interface. It can stabilize the interface very effectively. When only solid lipids are used, the hydrophobic solid-water interface is formed at room temperature rather than forming a fluid oil-water interface, so even if the hydrated liquid crystal phase by phospholipids is present at the hydrophobic solid-water interface, the stabilization effect of the interface is somewhat inferior. Can be.

The lipid and the colloidal solution may be 1:1 to 1:0.01 by weight, specifically 1:0.8 to 1:0.1, and more specifically 1:0.7 to 1:0.3, but are not limited thereto. .

The water-in-oil dispersion is not limited unless it inhibits the object of the present invention, but can be prepared by mixing the colloidal solution after heating the lipid to form a solution phase. When the lipid is heated, the temperature may be selected according to the type, molecular weight, and content of the lipid, and preferably, may be a temperature above a melting point at which the lipid is converted into a liquid phase. For example, it may be in the range of 50 to 100°C, preferably 60 to 95°C, more preferably 70 to 90°C, but is not limited thereto.

After adding the colloidal solution to the lipid to generate a water-in-oil dispersion, the water-in-oil dispersion is introduced into an aqueous solution containing a surfactant and homogenized to produce a nanolipid transporter.

In the step of generating a nanolipid transporter by introducing the water-in-oil dispersion into an aqueous solution containing the surfactant and homogenizing the surfactant, the surfactant is not limited, but may include an aliphatic glyceryl-based compound. have.

Preferably, the HLB of the surfactant may be 10 or more. The HLB value (Hydrophile-Lipophile Balance) is a value indicating the degree of affinity of the 활성제surfactant to the 　hydrophilic substance and 유ophilic substance, and as the HLB value approaches 0, it exhibits lipophilicity and approaches 40 Shows hydrophilicity. The surfactant according to the embodiment of the present invention may have an HLB value of 10 or more, preferably 10 to 25, more preferably an aliphatic glyceryl-based compound having 12 to 20, but is not limited thereto. In the above range, the stability of the aqueous dispersion is improved when the nanolipid transporter is formed, and an effect that the aqueous dispersion is more homogenized can be obtained, which is preferable.

The aliphatic glyceryl-based compound surfactant may be a polyglyceryl nonionic surfactant, and specific examples thereof include polyglyceryl fatty acid ester-based compounds, polyglyceryl aliphatic ether-based compounds, polyglyceryl sorbitan fatty acid esters, and among them. And any one or more selected from the group consisting of two or more combinations. More specific examples include polyglyceryl-4 caprylate/caprate, polyglyceryl-5 caprylate/caprate, polyglyceryl- 6 Caprylate/caprate, polyglyceryl-7 caprylate/caprate, polyglyceryl-8 caprylate/caprate, polyglyceryl-9 caprylate/caprate,　polyglyceryl-10　ka Prilate/caprate, polyglyceryl-4 caprate, polyglyceryl-5 caprate, polyglyceryl-6 caprate, polyglyceryl-7 caprate, polyglyceryl-8 caprate, polyglyceryl- 9 Caprate,　polyglyceryl-10　caprate, polyglyceryl-4 laurate, polyglyceryl-5 laurate, polyglyceryl-6 laurate, polyglyceryl-7 laurate, polyglyceryl-8 laur Rate, polyglyceryl-9 laurate, 　polyglyceryl-10 urarate, polyglyceryl-6 cocoate, polyglyceryl-7 cocoate, polyglyceryl-8 cocoate, polyglyceryl-9 cocoate, Polyglyceryl-10　 cocoate, polyglyceryl-11 cocoate, polyglyceryl-12 cocoate, polyglyceryl-6 myristate, polyglyceryl-7 myristate, polyglyceryl-8 myristate, polyglyceryl Reel-9 myristate, 　polyglyceryl-10　 myristate, polyglyceryl-11 myristate, polyglyceryl-12 myristate, 　polyglyceryl-10　oleate, polyglyceryl-11 oleate, polyglyceryl- 12 oleate,　polyglyceryl-10　stearate, polyglyceryl-11stearate, polyglyceryl-12stearate, and one or more selected from the group consisting of combinations of two or more of them. It is not.

The surfactant may be 0.01% to 15% by weight in aqueous solution, specifically 0.1% to 10% by weight, and more specifically 0.5% to 5% by weight, but is not limited thereto.

The aqueous solution containing the surfactant may further include alcohol, and the alcohol may be selected from lower alcohols having 1 to 4 carbon atoms, preferably ethanol, but is not limited thereto. When the alcohol is mixed with water, a water-alcohol co-solvent is formed and the surfactant has a form dissolved in the co-solvent. The mixing ratio of water and alcohol in the water-alcohol co-solvent may be 10:1 to 10:10 by weight, specifically 10:5 to 10:9. The use of a water-alcohol co-solvent is preferred in that it is possible to obtain a nanolipid transporter having a smaller particle size even at low energy during homogenization and to have high dispersion stability.

The homogenizing step may be to homogenize the nanolipid transporter with a homo mixer at 500 rpm or more, preferably 3,000 to 5,000 RPM for 5 minutes or more, and preferably 10 to 20 minutes.

The step of generating the nanolipid transporter may further include a high pressure emulsification step, preferably for homogenization. By going through the high-pressure emulsification step, it contains a relatively high content of physiologically active substances, yet has the appearance of a transparent or suspended liquid, and is differentiated from being absorbed as when applying the transparent or suspended liquid to the skin or hair follicles as an emulsion. It is preferable because it can provide a feeling of use and can exhibit excellent absorption characteristics specifically for hair follicles.

More specifically, the high-pressure emulsification step includes a further homogenization by passing at least one time, preferably 2 to 5 times, at a pressure of 100 bar or more, preferably 100 to 1500 bar, more preferably 500 to 1500 bar, with a high pressure emulsifier. can do. By going through the above steps, uniform nanoparticles can be formed more easily, and it is advantageous to produce a nanolipid transporter in a large capacity.

Hereinafter will be described in detail with respect to the nanolipid transporter encapsulated bioactive material of the present invention.

Referring to FIG. 1, FIG. 1 shows a schematic diagram of an example of a nanolipid transporter according to the present invention, wherein the nanolipid transporter according to the present invention comprises a hydrophilic polymer complex containing a bioactive substance and a hydrophilic polymer. Core portion comprising; And a shell portion located on the surface of the core and including lipids.

In addition, the core portion further includes phospholipids. The hydrophilic polymer composite included in the core portion forms an interface with lipids, and a hydrated liquid crystal phase by phospholipids is disposed on the interface to stabilize the interface very effectively. Accordingly, the physiologically active substance contained in the core portion may not be easily eluted to the outside, and is not eluted into the aqueous solution phase as a trauma in the homogenization or high-pressure emulsification step during the manufacturing process, and is stably enclosed in the shell portion even when present in the form of an aqueous dispersion. Can exist.

The bioactive material is not limited as long as it does not interfere with the object of the present invention, but 0.0001 to 20% by weight, preferably 0.005 to 10% by weight, more preferably 0.002 to 3% by weight, most preferably 0.001 to It may be 1% by weight.

In the hydrophilic polymer complex containing the bioactive material and hydrophilic polymer, the bioactive material and hydrophilic polymer may be combined in a weight ratio of 2000:1 to 20:1, specifically 1000:1 to 40:1, and physiological in the above range. It is preferable because the encapsulation efficiency of the active material can be improved.

The lipids and phospholipids are not limited as long as they do not inhibit the object of the present invention, but may be included in a weight ratio of 100:0.1 to 100:50, specifically 100:0.5 to 100:25, and more specifically 100:1 to 100:10. have.

The nanolipid transporter is not limited as long as it does not inhibit the object of the present invention, but may have an average particle diameter of 20 nm to 1000 nm, specifically 40 to 700 nm, more specifically 50 to 500 nm, and satisfy the following relational expression (1) have.

[Relationship 1]

|T ₀ -T ₂₀ |/T ₀ <0.2

(In the relational formula 1, T ₀ means the transmittance measured at 500 nm wavelength after the preparation of the 1% by weight aqueous dispersion of the nanolipid transporter, T ₂₀ is 500% after leaving the 1% by weight aqueous dispersion of the nanolipid transporter at 45°C for 20 days. It means transmittance measured at nm wavelength.)

The nanolipid transporter according to the present invention may have a value of dispersion stability, specifically defined by the relational expression 1, below 0.1. That is, the nanolipid transporter has excellent dispersion stability, and discoloration or layer separation of the nanolipid transporter does not occur, and even when it is left for a long time, problems such as poor stability due to aggregation phenomenon do not occur.

In addition, the present invention provides a cosmetic composition comprising the nanolipid transporter.

In the present invention, the cosmetic composition is not limited, but any one selected from the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, oils, powder foundations, emulsion foundations, wax foundations and sprays It may be one formulation.

The cosmetic composition may include ingredients commonly used in cosmetics in addition to the nanolipid transporter as an active ingredient, and include, for example, antioxidants, stabilizers, solubilizers, conventional adjuvants such as vitamins, pigments and fragrances, and carriers can do.

On the other hand, the cosmetic composition may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleaning , Oil, powder foundation, emulsion foundation, wax foundation and spray. However, it is not necessarily limited thereto. More specifically, it can be prepared in the form of flexible lotion, converging lotion, nutrition lotion, nutrition cream, massage cream, essence, pack, spray or powder.

When the formulation of the cosmetic composition is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components. Can be.

In addition, when the formulation of the cosmetic product of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and particularly in the case of a spray, additionally chlorofluoro Propellants such as hydrocarbon, propane/butane or dimethyl ether.

Further, when the formulation of the cosmetic product of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan can be used.

In addition, when the formulation of the cosmetic product of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol as carrier components, suspensions such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester Agents, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or trakant, etc. can be used.

As a preferred example, the cosmetic composition comprising the nanolipid transporter may be a cosmetic composition for transdermal absorption having targeting properties for hair follicles.

The nanolipid transporter has excellent affinity for hair follicles because the shell portion contains lipids, and has a particle size of tens to hundreds of nm, so it can have excellent targeting properties by having excellent absorption capacity specifically for hair follicles. Due to these hair follicle targeting properties, the nanolipid transporter treated on the skin can be intensively accumulated in the center of the hair follicle along the hair follicle, and can be absorbed from the inside of the hair follicle to the dermis. The nanolipid transporter absorbed by the dermis can impart a treatment or improvement effect through the bioactive material by releasing the bioactive material contained in the core.

As a non-limiting example, the cosmetic composition for transdermal absorption containing the nanolipid transporter may be targeted to the hair follicles by treating the scalp. The treatment may include conventionally known means, such as spraying or application, and nano-lipid transporters may be targeted to the hair follicles present on the scalp as a dosing device through a hand or an application device, and bioactive substances may be targeted through the targeting of the hair follicles. It can be supplied to the scalp to obtain an excellent effect of preventing hair growth and hair loss.

In other words, for the purpose of preventing hair loss, hair growth, or hair removal, scalp tissue with a large distribution of hair follicles requires a delivery agent that is efficiently delivered to the hair follicle rather than transdermal delivery, and the hair follicle is the tissue that can be quickly connected to blood. . Since the nanolipid transporter according to the present invention has the same graininess as the solid lipid nanoparticles than the colloidal transporter such as liposomes, it is possible to obtain a faster and more effective improvement effect when treating the hair follicles.

Hereinafter, the contents of the present invention will be described in more detail through examples. The examples are only intended to illustrate the present invention in more detail, and the scope of the present invention is not limited by them.

[Example 1] Preparation of Nano Lipid Carriers (NLC)

It was prepared so that the nanolipid transporter 100g through the following manufacturing method.

As a peptide, Copper TriPeptide-1 (CTP) and Alanine/Histidine/Lysine Polypeptide Copper HCl (ATP) are added to purified water and dissolved to prepare a peptide aqueous solution. Did. The peptide was made to be 0.0225% by weight in the total nanolipid transporter dispersion.

A 0.1 wt% Carbomer aqueous solution was added to the dissolved peptide aqueous solution, and dispersed at 500 RPM through magnetic stirring at 70°C. After preparation, the carbomer was set to 0.000125% by weight in the total nanolipid transporter dispersion. Through the above process, an aqueous solution of a hydrophilic polymer complex in the form of a peptide-hydrogel was prepared.

To prepare a phospholipid solution, hydrogenated lecithin (hydrogenated lecithin) was prepared by dissolving in ethanol. In detail, ethanol used in the phospholipid solution was prepared to be 0.8% by weight of the aqueous dispersion of nanolipid transporter, and the hydrolyzed lecithin was added to the ethanol and stirred at 500RPM at 70°C to completely dissolve to prepare a transparent phospholipid solution. Did.

To the phospholipid solution prepared through the above process, the aqueous solution of the hydrophilic polymer complex in the form of a pre-prepared peptide-hydrogel is added and mixed evenly at 700 RPM for 5 minutes, hydrated in a phospholipid solution to prepare a hydrated liquid to be encapsulated in the nanolipid transporter. A core portion was formed.

Subsequently, the solid first lipid, glyceryl distearate, and the liquid second lipid, caprylic/capric triglyceride, were dissolved by stirring at 70° C. at 500 rpm for clarity. Made into solution phase. A solution containing a core portion in the form of a hydrated liquid was added to the lipid mixture on a transparent solution, and stirred at 700°C for 10 minutes at 70° C. to prepare a water-in-oil dispersion.

While stirring the water-in-oil dispersion in purified water/ethanol mixture in which polyglyceryl-10 oleate having a HLB of 15.9 as a surfactant was dissolved, stirring was performed at 2,000 rpm for 15 minutes with a Homodisperser (Model 2.5, PRIMIX). Did. At this time, the ethanol mixed with the surfactant was mixed to be 40% by weight of the total aqueous dispersion of nanolipids.

The stirred solution was further homogenized by proceeding with a homomixer at 5,000 rpm for 20 minutes, and then a high pressure emulsifier (Microfluidics, M-110P microfluidizer) was used for high pressure emulsification. Additional homogenization was performed in 3 runs. Subsequently, the homogenized solution was slowly cooled at room temperature to finally prepare a nanolipid transporter dispersion, and the contents of the components included in the nanolipid transporter dispersion are listed in Table 1.

[Example 2]

In Example 1, the ethanol content of the solution in which the surfactant was dissolved was reduced to 1/5 to make 8% of the total nanolipid transporter, and the rest of the procedure was the same to prepare an aqueous dispersion of nanolipid transporter. The contents of the components included in the aqueous dispersion of nanolipid transporters are listed in Table 1.

[Example 3]

In Example 1, the amount of addition of carbomer was increased to 4 times to make 0.0005% by weight of the total nanolipid transporter, and the rest of the procedure was the same to prepare a nanolipid transporter dispersion. The contents of the components included in the aqueous dispersion of nanolipid transporters are listed in Table 1.

[Example 4]

In Example 1, the rest of the procedure was the same as that of the nanolipid transporter, except that the content of the second lipid, caprylic/capric triglyceride, was reduced to 1/2 to make 0.9375% by weight of the total nanolipid transporter. An aqueous dispersion was prepared. The contents of the components included in the aqueous dispersion of nanolipid transporters are listed in Table 1.

Table 1 below shows the composition ratios of Examples 1 to 4 and the homogenization by high pressure emulsification.

Ingredient name Unit: Weight% (Based on 100 g of nano lipid transporter) Example 1 Example 2 Example 3 Example 4 Copper peptide-1 0.0225 0.0225 0.0225 0.0225 Alanine/Histidine/Lysine Polypeptide Copper HCC 0.0025 0.0025 0.0025 0.0025 Carbomer 0.000125 0.000125 0.0005 0.000125 Purified water 0.874875 0.874875 0.8745 0.874875 Hydrogenated lecithin 0.15 0.15 0.15 0.15 Ethanol (preparation of phospholipid solution) 0.8 0.8 0.8 0.8 Glyceryl distearate 1.875 1.875 1.875 1.875 Caprylic/Capric Triglyceride 1.875 1.875 1.875 0.9375 Polyglyceryl-10 oleate 2.5 2.5 2.5 2.5 ethanol 40 8 40 40 Purified water up to 100 up to 100 up to 100 up to 100 High pressure emulsification O O O O

[Example 5]

In Example 1, except for omitting the high pressure emulsification homogenization process, the rest of the procedure was the same to prepare a nanolipid transporter dispersion.

[Comparative Example 1]

In Example 1, the hydrogel, a carbomer, was not added, and the rest of the procedure was the same to prepare a nanolipid transporter dispersion.

[Comparative Example 2]

In Example 2, except for using sorbitan palmitate (Sorbitan Palmitate) instead of the surfactant polyglyceryl-10 oleate, the rest of the procedure was the same to prepare a nanolipid aqueous dispersion.

Table 2 below shows the composition ratio and homogenization of Example 5, Comparative Example 1 and Comparative Example 2 described above.

Ingredient name Unit: Weight% (Based on 100 g of nano lipid transporter) Example 5 Comparative Example 1 Comparative Example 2 Copper peptide-1 0.0225 0.0225 0.0225 Alanine/Histidine/Lysine Polypeptide Copper HCC 0.0025 0.0025 0.0025 Carbomer 0.000125 - 0.00025 Purified water 0.874875 0.875 0.87475 Hydrogenated lecithin 0.15 0.15 0.15 Ethanol (preparation of phospholipid solution) 0.8 0.8 0.8 Glyceryl distearate 1.875 1.875 1.875 Caprylic/Capric Triglyceride 1.875 1.875 1.875 Polyglyceryl-10 oleate 2.5 2.5 - Sorbitan palmitate - - 2.5 ethanol 40 40 40 Purified water up to 100 up to 100 up to 100 High pressure emulsification X O O

[Comparative Example 3]

In the phospholipid solution of Example 1, a nanolipid transporter was prepared in the same manner as the rest of the procedure, except that the ethanol solution was used without containing the phospholipid.

[Comparative Example 4]

In the lipid mixture of Example 1, a nanolipid transporter was prepared in the same manner as the rest of the procedure, except that 3.75% by weight of the solid first lipid was not used and the liquid second lipid was not used.

[Comparative Example 5]

A nanolipid transporter was prepared in the same manner as the rest of the procedure, except that 3.75% by weight of the second lipid in the liquid phase was not used in the lipid mixture of Example 1 without using the solid first lipid.

The properties of the composition were evaluated as follows for each of the experimental and comparative examples.

[Test Example 1] Measurement of nanolipid transporter particle size and permeability according to formulation composition ratio and high pressure homogeneity

In order to analyze the average particle size of the nanolipid transporter prepared from the Examples and Comparative Examples, the particle size was measured with a nanoparticle analyzer (Zetasizer Nano ZS, Malvern Instruments), and the transmittance measured at 500 nm after preparation of the nanolipid transporter To And after standing for 30 days at 45 ℃ to calculate the long-term stability value calculated by the following equation 1 from the transmittance measured at 500 nm wavelength are shown in Table 3.

[Relationship 1]

|T ₀ -T ₂₀ |/T ₀ <0.2

(In the above equations 1 T ₀ after the production of nano-lipid delivery system of 1% aqueous dispersion by weight means a permeability measured at 500 nm wavelength, and, T ₂₀ are 500 then the nano-lipid delivery system of 1% aqueous dispersion by weight to stand at 45 ℃ 20 il It means transmittance measured at nm wavelength.)

Particle size (nm) Long-term stability Example 1 246.1 0.081 Example 2 102.0 0.141 Example 3 261.0 0.132 Example 4 101.5 0.154 Example 5 > 5 μm 0.867 Comparative Example 1 1308.0 0.498 Comparative Example 2 > 5 μm 0.772 Comparative Example 3 378.2 0.245 Comparative Example 4 572.2 0.792 Comparative Example 5 218.2 0.855

Figure 2 shows the results of analyzing the particle size of Example 2.

For Examples 1 to 4, it was confirmed to have a particle size of approximately 300 nm or less, and long-term dispersion stability was also excellent. In the case of Example 5, a suspension having a cloudy appearance was obtained as a result of not homogenizing by high-pressure emulsification, an average particle size of 5 µm or more was observed, and dispersion stability was not good as it had a large particle size.

On the other hand, in Comparative Examples 1, 2, 4, and 5, it was confirmed that nanoparticles having a slightly larger initial particle size were obtained, and that long-term dispersion stability was also poor, and thus it was difficult to utilize them as nanolipid transporters for cosmetic compositions. In the case of Comparative Example 3, nanoparticles having a slightly larger initial particle size were obtained, but long-term dispersion stability was found to be superior to that of other Comparative Examples.

[Test Example 2] Nano lipid transport stability analysis

Stability was measured for the nanolipid transporter solution prepared through the above Examples and Comparative Examples. Stability was measured to confirm discoloration, layer separation, etc. over time, under specific conditions of the prepared nanolipid transporter. In order to measure long-term dispersion stability, each nanolipid carrier aqueous dispersion was placed in a constant temperature chamber at which 45°C was maintained.

The change in morphology was visually observed based on the elapsed time of 1 day, 10 days, 20 days, and 30 days of the dispersion of the nanolipid transporter placed in the constant temperature chamber.

The results of confirming the aggregation, precipitation, etc. of the nanolipid transporter solution over time are as shown in Table 4, and FIG. 3 is a photograph of Example 1 and Comparative Example 1, which has passed 30 days through the stability experiment.

1 day 10 days 20 days 30 days Example 1 stability stability stability stability Example 2 stability stability stability Cohesion Example 3 stability stability stability Cohesion Example 4 stability stability stability Cohesion Example 5 Cohesion Sedimentation Sedimentation Sedimentation Comparative Example 1 stability Cohesion Sedimentation Sedimentation Comparative Example 2 Cohesion Sedimentation Sedimentation Sedimentation Comparative Example 3 stability stability stability Cohesion Comparative Example 4 stability Cohesion Sedimentation Sedimentation Comparative Example 5 stability Sedimentation Sedimentation Sedimentation

Looking at the results of Table 4, Example 1 showed stable dispersion stability up to 30 days, and Examples 2 to 4 showed stable dispersion stability up to 20 days, but some aggregation was observed from 30 days. . On the other hand, in the case of Example 5, since a micro particle having a large initial particle size was generated, a phenomenon of sedimentation was observed from the 10th.

On the other hand, precipitation or aggregation occurred seriously after 10 days of Comparative Examples 1, 2, 4 and 5, and in the case of Comparative Example 3, aggregation was observed from 30 days.

[Test Example 3] Measurement of encapsulation efficiency of bioactive components in nanolipid transporters

The nanolipid transporter solutions prepared from the above Examples and Comparative Examples were centrifuged at 4°C and 80,000 RPM for 30 minutes through a centrifuge to separate the supernatant and precipitate. Subsequently, the supernatant was collected and calculated by measuring the concentration of the unencapsulated peptide, and the calculation method of the unencapsulated peptide and encapsulation efficiency can be obtained from Equation 2 below.

[Relationship 2]

EE _Free = (W _Total -W _Free )/W _Total x 100

In Equation 2, EE _Free means the standard (peptide) encapsulation efficiency, W _Total means the total standard concentration, and W _Free means the unenclosed standard concentration. Table 5 below shows the encapsulation efficiency as a result of the experiment.

Encapsulation efficiency (%) Example 1 93.26 Example 2 90.57 Example 3 91.21 Example 4 89.40 Example 5 92.78 Comparative Example 1 83.92 Comparative Example 2 76.28 Comparative Example 3 44.13 Comparative Example 4 56.63 Comparative Example 5 47.12

From the results of Table 5, in Examples 1 to 5 of the present invention, the encapsulation efficiency was excellent over 89%, whereas in Comparative Examples 1 to 5, the encapsulation efficiency was remarkably low.

[Test Example 4] Measurement of follicle-specific nanolipid transporter particles using bio-TEM

The experiment of measuring the nanolipid transporter produced in Example 1 with Bio-TEM (Bio-Transmission Electron Microscope, HITACHI H-7650) was performed. The sample solution was measured by sampling with a 200 mesh grid through cryo treatment.

The measurement results of the particles imaged with Bio-TEM are shown in FIG. 4. FIG. 4 is an image of a nanolipid transporter mounted on a grid, and as can be seen from this, it can be seen that the nanolipid transporter is formed in a uniform and solid particle form of about 100 nm.

[Test Example 5] Measurement of follicle-specific nanolipid transporter absorption behavior using a confocal laser scanning microscope

The nano lipid transporter prepared in Example 1 was treated with a fluorescent substance, Fluorescein isothiocyanate (FITC), and experiments were performed to observe the absorption of the skin.

A MicroPig membrane was used for the absorption experiment, and the MicroPig membrane was frozen with liquid nitrogen and then sliced to 8um through a precision grinder. The crushed tissue was transferred to a slide glass and then observed by a confocal microscope after applying the Mouting reagent.

FIG. 5 is an image of the shape in which the FITC-treated nanolipid transporter is absorbed in the ruptured tissue, and it can be seen that the nanolipid transporter is absorbed along the hair of the hair follicle, and gradually moves from the inside of the hair follicle to the dermis. It was confirmed that the lipid transporter was being absorbed.

[Test Example 6] Nanolipid transporter skin absorption capacity test

The nanolipid transporter of Example 1 and the physiologically active substance aqueous solution were respectively applied to a micropig membrane fixed to a skin diffusion device (Franz Diffusion Cell) to confirm the absorption amount of the nanolipid transporter.

The nanolipid transporter that penetrated the artificial skin was pretreated. Specifically, 1 ml of the sample was added to 2.5 ml of ethanol, 2 ml of chloroform, and 0.5 ml of purified water to destroy the nanolipid transporter that penetrated the artificial skin, followed by voltexing, and centrifuged at 4000 rpm for 10 minutes to extract only the supernatant. The active ingredient was extracted from the pre-treated nanolipid transporter and content analysis was performed through HPLC.

Content analysis results through HPLC are shown in Table 6, Table 7 and FIG. 6. Specifically, Table 6 shows the absorption amount for each time zone.

Cumulative permeation amount of skin-permeable bioactive substance (μg/cm ² ) 0h 1h 2h 4h 7h 10h 24h Example 1 average 0.00 42.60 100.81 110.47 129.54 140.74 154.34 stdev 0.00 85.20 116.42 128.68 150.41 163.14 178.31 Bioactive substance aqueous solution average 0.00 41.70 50.86 59.37 111.30 131.06 150.94 stdev 0.00 83.41 101.72 118.73 133.81 155.85 178.05

Cumulative permeation of bioactive substances that have penetrated the skin Flux (μg/hr*cm ² ) K _p (cm/hr*10 ^-4 ) Example 1 26.61 ± 17.05 1565.02 ± 1002.74 Physiologically active substance aqueous solution 19.55 ± 12.48 1303.03 ± 831.74

FIG. 6 is a graph analyzing the absorbed content of the nanolipid transporter of Example 1 and the aqueous solution of physiologically active substances over time, and was confirmed to have a high absorption rate and a fast absorption time zone in the experimental group coated with the nanolipid transporter for each time zone. Particularly, 2 hours after the first administration, a cumulative permeation amount was almost twice as fast as the control group, and a new effect was found, indicating an immediate administration effect upon the first administration.

From the above results, the nanolipid transporter through the present invention can maintain a stable structure without spilling physiologically active substances to the outside for a long period of time, and the encapsulation efficiency of the physiologically active substances is not only excellent compared to the control group, but also the cumulative permeation amount during skin administration It was confirmed that the physiologically active substance was about 36% higher than the direct administration, and when administered to the hair follicles, it had a remarkably high permeation rate twice or more compared to normal skin. From this, it was confirmed that the nanolipid delivery system of the present invention has an excellent effect as a follicle targeting drug delivery system.

Claims (5)

A core portion comprising a hydrophilic polymer complex containing a bioactive substance and a hydrophilic polymer; And
Located on the surface of the core and the shell portion containing a lipid; includes, the core portion nanolipid transporter further comprises a phospholipid. According to claim 1,
The lipid and phospholipids are included in a weight ratio of 100:0.1 to 100:50, nanolipid transporter. According to claim 1,
The bioactive material and the hydrophilic polymer are contained in a weight ratio of 2000:1 to 20:1, nanolipid transporter. According to claim 1,
The nanolipid transporter has an average particle diameter of 20 nm to 1000 nm, and satisfies the following relationship 1, nanolipid transporter.
[Relationship 1]
|T ₀ -T ₂₀ |/T ₀ <0.2
(In the above equations 1 T ₀ after the production of nano-lipid delivery system of 1% aqueous dispersion by weight means a permeability measured at 500 nm wavelength, and, T ₂₀ are 500 then the nano-lipid delivery system of 1% aqueous dispersion by weight to stand at 45 ℃ 20 il It means transmittance measured at nm wavelength.) A cosmetic composition comprising the nanolipid transporter of any one of claims 1 to 4.

Images